Bortezomib is a new chemotherapeutic agent approved for the treatment of relapsed/refractory and newly diagnosed multiple myeloma. One of the major side effects of bortezomib is a peripheral length-dependent sensory axonal neuropathy and, less frequently, a small fiber neuropathy. Autonomic symptoms like postural dizziness, syncope, diarrhoea, ileus, impotence and urinary disturbances have been reported, nevertheless, autonomic neuropathy has never been characterized. We describe by means of immunofluorescence, the involvement of autonomic skin nerve fibers in three patients with small fiber neuropathy induced by bortezomib treatment
Giannoccaro M.P., Donadio V., Gomis Pèrez C., Borsini W., Di Stasi V., Liguori R. (2011). Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study. NEUROLOGICAL SCIENCES, 32(2), 361-363 [10.1007/s10072-010-0475-2].
Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study.
Giannoccaro M. P.;DI STASI, VITANTONIO;LIGUORI, ROCCO
2011
Abstract
Bortezomib is a new chemotherapeutic agent approved for the treatment of relapsed/refractory and newly diagnosed multiple myeloma. One of the major side effects of bortezomib is a peripheral length-dependent sensory axonal neuropathy and, less frequently, a small fiber neuropathy. Autonomic symptoms like postural dizziness, syncope, diarrhoea, ileus, impotence and urinary disturbances have been reported, nevertheless, autonomic neuropathy has never been characterized. We describe by means of immunofluorescence, the involvement of autonomic skin nerve fibers in three patients with small fiber neuropathy induced by bortezomib treatmentI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
